Eli Lilly & Co. (NYSE: LLY) and AstraZeneca (NYSE: AZN) announced an extension to their existing immuno-oncology collaboration exploring novel ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Lilly and AstraZeneca Expand Immuno-Oncology Research Collaboration with New CombinationsOctober 22, 2015 6:20 AM Lilly supports global Dementia Discovery FundOctober 21, 2015 6:30 AM